Le Lézard
Classified in: Health, Science and technology, Business
Subject: CXP

Swift Biosciences Growth Sparks Expansion Into New Headquarters & First West Coast Office

ANN ARBOR, Mich. and SOUTH SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ -- Swift Biosciences, a leading provider of innovative library-prep solutions for genomic sequencing, today announced the move and expansion of their headquarters in Ann Arbor, Michigan, and the opening of an office in the San Francisco Bay Area. These new facilities in two fast-growing marketplaces will enable Swift to expand its manufacturing capabilities, commercial partnerships, and sales and technical support resources. 

Swift is moving its headquarters to a 17,570-square-foot technology lab located within the Michigan Innovation Headquarters (MI-HQ) in Ann Arbor. MI-HQ, which will house the manufacturing of Swift's novel library preparation solutions for emerging applications in next-generation sequencing (NGS), is advantageously located near the University of Michigan and other life science, pharma, biotech and high-tech companies.

Swift will be doubling their current research and development, and manufacturing space in Ann Arbor to accelerate the company's growth and resource requirements. Swift's new Class-A laboratory?opening in November 2017?will feature an open floor plan that will foster collaboration, improve overall workflow, and give the company space and flexibility to evolve with future business needs.

In addition to Swift's growth and expansion in the Midwest, the company will open a new South San Francisco office this month. The Bay Area location offers important strategic advantages, including regional access to established and emerging hubs for NGS such as San Diego, Los Angeles, Seattle and the Pacific Rim.

Additionally, the company will neighbor biotech leaders within the Biotech Bay such as ThermoFisher and Illumina; will be in close proximity to strategic partners such as Fluxion Biosciences; and will be easily accessible to major research institutions including UC San Francisco, Gladstone Institutes, Stanford University, UC Berkeley and Joint Genome Institute.

"Expanding into the San Francisco market was an important commitment for our company that will help us better leverage the diverse biotech industry and capitalize on the exceptional and diverse talent pool," stated Mark Lewis, Chief Executive Officer of Swift Biosciences. "We will have an active and visible presence at the geographic center of our industry, and in a region that received more than $5 billion in National Institutes of Health funding last year."

Both the Ann Arbor and South San Francisco offices are well positioned to better facilitate networking and collaboration with major institutions and commercial partners on new applications, expand technology capability and develop more efficient, integrated genomic workflow solutions. 

"Our goal at Swift is to enable scientists to generate the highest quality products and ideas, in an effort to push the boundaries of science," stated Lewis. "We have continued to grow immensely in size and capability, which has given us the opportunity to position ourselves at the forefront of genomic sequencing applications."

With the development and opening of Swift's two new locations, the company is able to expand in manufacturing, sales and technical support for its customers, while also providing more jobs and opportunities within the biotechnology industry in both Michigan and California.

SOURCE Swift Biosciences

These press releases may also interest you

at 03:00
LUGANO, Switzerland, October 19, 2017 /PRNewswire/ -- ESMO, the leading professional organisation for medical oncology, has granted the newly established ESMO Award for Immuno-Oncology to Prof Laurence Zitvogel for her innovating and internationally...

at 02:16
UPPSALA, Sweden, Oct.19, 2017 /PRNewswire/ -- Financial overview Q3 2017 Total net revenues SEK 166.2 million (181.9) Zubsolv® US net revenue SEK 121.1 million (142.4) EBIT SEK 40.9 million (43.0) EBITDA SEK 46.1 million (50.9) Earnings per...

at 02:03
MyoVista® hsECGtm Utilizes Wavelet Technology to Detect Cardiac Diastolic Dysfunction SOUTHLAKE, Texas, Oct. 19, 2017 /PRNewswire/ -- HeartSciences announced today the commercial launch of its MyoVista® high sensitivity electrocardiograph...

at 02:00
- Company's Carlsbad manufacturing facility passes FDA and EMA inspections - Underscores capabilities as commercial manufacturer of viral and gene therapy products - Highlights position as leading contract manufacturing organization (CMO) for...

at 02:00
LONDON, Oct. 19, 2017 /PRNewswire/ -- Benson Hill Biosystems, an agricultural technology company dedicated to unlocking the natural genetic potential of plants, today announced at the Future Food-Tech Conference the commercial launch of Edit, powered...

at 02:00
- Company's Carlsbad, U.S., manufacturing facility passes FDA and EMA inspections - Underscores capabilities as commercial manufacturer of viral and gene therapy products - Highlights position as leading contract manufacturing organization (CMO)...

News published on 5 october 2017 at 15:20 and distributed by: